A phase II study of recombinant tumor necrosis factor in renal cell carcinoma : a study of the national cancer institute of Canada clinical trials group

The National Cancer Institute (NCI) Canada Clinical Trials Group conducted a phase II study of recombinant tumor necrosis factor (rTNF) given intravenously daily for 5 days every other week, in measurable metastatic renal cell carcinoma. Two of 26 patients responded with responses lasting greater th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of immunotherapy 1992, Vol.11 (1), p.67-70
Hauptverfasser:	SKILLINGS, J, WIERZBICKI, R, EISENHAUER, E, VENNER, P, LETENDRE, F, STEWART, D, WEINERMAN, B
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic agents Biological and medical sciences Carcinoma - diagnostic imaging Carcinoma - pathology Carcinoma - therapy Drug Evaluation Female Humans Immunotherapy Kidney Neoplasms - diagnostic imaging Kidney Neoplasms - pathology Kidney Neoplasms - therapy Male Medical sciences Middle Aged Pharmacology. Drug treatments Recombinant Proteins - therapeutic use Tomography, X-Ray Computed Tumor Necrosis Factor-alpha - adverse effects Tumor Necrosis Factor-alpha - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!